UNSPSC 51172900: Combination genito-urinary agents

This classification denotes combination drugs and preparations that treat diseases and disorders of the organs involved in reproduction and the formation and release of urine, which include the genitals, hence the term GENITO-URINARY AGENTS. Typical combination genito-urinary agent constituents are boric, glycerin, inositol, menthol, methyl salicylate, octoxynol 9, oxyquinoline, sodium acid pyrophosphate, sodium citrate, and tamsulosin.

UNSPSC 51172900 Combination genito-urinary agents is a Class code that in recent state and local procurement activity encompasses chemical supply for municipal water treatment and generic pharmaceutical and over-the-counter product distribution across government health and facilities operations. The two recent opportunities posted under this code reflect a divergence in scope: the City of Meriden's bid solicitation (B027-15) is for sodium bisulfite, a chemical used in water pollution control facilities, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP solicits manufacturers of generic pharmaceuticals and OTC products for distribution across state and local government facilities in Minnesota and Oregon. The latter is the primary activity and better reflects the code's nominal scope. Issuing bodies include municipalities (the City of Meriden, Connecticut) and cooperative purchasing vehicles administered by state procurement offices (MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement).

Activity under this code spans Connecticut and Minnesota with Oregon participation in the MMCAP cooperative. The most recent and largest opportunity is the MMCAP generic multi-source pharmaceuticals and OTC products RFP, posted January 20, 2026, with a response deadline of March 26, 2026; awarded vendors will be provided to three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) by May 15, 2026, with contracts effective July 1, 2026 for a two-year term. Evaluation weights 75 percent on price competitiveness, with 10 percent on fixed pricing, 5 percent each on compliance with administrative data formats, EDI capability, and agreement to a 3 percent administrative fee. Vendors must maintain commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). The City of Meriden's sodium bisulfite procurement (B027-15) is due July 29, 2026, requiring General Liability of $1,000,000 to $2,000,000 and performance and payment bonds.